Product Highlights

Product Summary

AtopX®, based on our original Hexagen® formula, employs advanced healing technology to soothe and manage the symptoms of atopic, irritant, and radiation dermatoses.


AtopX® is indicated for the management of atopic, irritant, and radiation dermatoses.

About Atopic Dermatitis

What is Eczema?

Atopic dermatitis is a common, often persistent skin disease that affects a large percentage of the world’s population. There is a known hereditary component of the disease, and it is more common in affected families. The term dermatitis means inflammation of the skin. Many physicians and patients use the term eczema when they are referring to this condition. Eczema is a widespread affliction affecting the lives of millions of children and adults.

Key Facts

31.6 million Americans are estimated to have symptoms of eczema, including 17.8 million with symptoms of atopic dermatitis.

  • Worldwide, about 20% of children and up to 3% of the adult population have some form of eczema.
  • Those who live in developed countries or colder climates seem to be more prone to developing eczema.
  • Hand dermatitis accounts for 20–35% of all U.S. eczema cases, affecting up to 10% of the U.S. population.
  • In a 2007 U.S. survey, just over one‐third (37.1%) of those with eczema symptoms reported a physician diagnosis.

Our Response

Recent research has shown eczema prone individuals to be more heavily colonized with Staphylococcus Aureus than the non-eczema afflicted population (Miller, Johns Hopkins Medicine, 2018). This same research has directly connected chemical byproducts (Delta Toxins) of this colonized bacteria with the skin-based inflammation we know as “eczema.”

At Turn Therapeutics®, our goal is to address this root cause of inflammation, namely excess bioburden, all the while soothing symptoms and maintaining moisture balance.

Turn Therapeutics Reaches Licensing and Distribution Agreement with MIMEDX